Alunbrig (brigatinib) — United Healthcare

Initial criteria

• Diagnosis of inflammatory myofibroblastic tumor (IMT)
• Presence of ALK translocation

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Alunbrig therapy

Approval duration

12 months